7QD Stock Chart & Stats
€3.90
-€0.10(-2.50%)
At close: 4:00 PM EDT
€3.90
-€0.10(-2.50%)
Day’s Range― - ―
52-Week Range€1.41 - €4.92
Previous CloseN/A
Volume272.00
Average Volume (3M)64.00
Market Cap
€1.90B
Enterprise Value€937.20
Total Cash (Recent Filing)€201.32M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 09, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding430,969,400
10 Day Avg. Volume27
30 Day Avg. Volume64
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.94
Price to Sales (P/S)0.63
P/FCF Ratio-17.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.54Price Target Upside16.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.03
Revenue Forecast (FY)€2.55B
Bulls Say, Bears Say
Bulls Say
Membership & Revenue GrowthSustained double‑digit enrollment and revenue growth reflects strong product-market fit in Medicare Advantage. Durable membership expansion increases premium revenue, spreads fixed costs, and supports longer-term margin improvement as cohorts mature and utilization normalizes, strengthening unit economics.
Strong Balance Sheet (No Debt)A low‑leverage balance sheet with growing assets and stable equity provides financial flexibility to self‑fund growth, invest in clinical tools, and weather industry shocks. This reduces refinancing risk and preserves strategic optionality while management executes scale and cohort maturation plans.
Positive Operating Cash Flow & FCFRecent meaningful positive operating and free cash flow supports internal funding of membership growth and clinical programs without debt. If maintained across cycles, consistent FCF will underpin sustainable investment in care management and margins, though past volatility warrants monitoring for durability.
Bears Say
Inconsistent Full‑Year ProfitabilityAlthough trailing results approach break‑even, full‑year losses persist, exposing the model to swings in medical costs, pricing, and seasonality. Until multi‑year profitability is established, margins and equity remain vulnerable to adverse claim trends or reimbursement shifts.
High Share Of Early‑Stage CohortsA large proportion of members are in year‑one cohorts with weaker unit economics; cohort maturation typically drives margin gains but the current mix delays sustainable profitability. Reliance on cohort improvement means results remain sensitive to retention and clinical program execution.
Regulatory / CMS Litigation RiskStar ratings materially affect quality bonuses, bidding flexibility, and expected revenue. Ongoing legal uncertainty and a possible CMS reversal could remove projected bonus income and alter 2027 strategy, creating a structural risk to forward profitability and product positioning.
Clover Health Investments News
7QD FAQ
What was Clover Health Investments’s price range in the past 12 months?
Clover Health Investments lowest stock price was €1.41 and its highest was €4.92 in the past 12 months.
What is Clover Health Investments’s market cap?
Clover Health Investments’s market cap is €1.90B.
When is Clover Health Investments’s upcoming earnings report date?
Clover Health Investments’s upcoming earnings report date is Nov 09, 2026 which is in 95 days.
How were Clover Health Investments’s earnings last quarter?
Clover Health Investments released its earnings results on Aug 05, 2026. The company reported €0.063 earnings per share for the quarter, beating the consensus estimate of €0.034 by €0.029.
Is Clover Health Investments overvalued?
According to Wall Street analysts Clover Health Investments’s price is currently Undervalued.
Does Clover Health Investments pay dividends?
Clover Health Investments does not currently pay dividends.
What is Clover Health Investments’s EPS estimate?
Clover Health Investments’s EPS estimate is <0.01.
How many shares outstanding does Clover Health Investments have?
Clover Health Investments has 430,969,400 shares outstanding.
What happened to Clover Health Investments’s price movement after its last earnings report?
Clover Health Investments reported an EPS of €0.063 in its last earnings report, beating expectations of €0.034. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Clover Health Investments?
Currently, no hedge funds are holding shares in DE:7QD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Health Investments Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.54 (16.48% Upside)
€4.54 (16.48% Upside)
Blogger Sentiment
Bullish
DE:7QD Sentiment 80%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth €497.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.53%
Trailing 12-Months
Company Description
Clover Health Investments
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) health plans for individuals eligible for Medicare. In addition to its insurance operations, Clover Health also engages in non-insurance-related business ventures. The company was established in 2014 and its main office is located in Franklin, Tennessee.
7QD Company Deck
7QD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong top-line and membership growth (48% MA growth, +56% revenue YoY in Q2), improving profitability (Q2 adjusted EBITDA $41M, GAAP net income $28M), expanded operating leverage, improved cash balance, and a favorable 4.5-star recalculation — all supported by visible cohort maturation dynamics (~$70 PMPM improvement year-over-year between vintages). Manageable lowlights include seasonal Q4 headwinds, a large share of early-stage members that will pressure near-term margins until cohorts mature, ongoing CMS appeal litigation risk, and elevated outpatient trends that require monitoring. Overall, the positive operational and financial momentum, upgraded guidance, and stronger star positioning outweigh the remaining risks and seasonal uncertainties.View all DE:7QD earnings summaries7QD Stock 12 Month Forecast
Average Price Target
€4.54
▲(16.48% Upside)